ACE-031 1mg

ACE-031 and follistatin both neutralize myostatin, but through different mechanisms with different selectivity profiles. ACE-031 is an ActRIIB decoy receptor that binds all ActRIIB ligands -- including myostatin, GDF-11, activin A, BMP9, and others. Follistatin binds a different set including myostatin, activins, and BMPs but has its own selectivity pattern. Neither provides pure myostatin-specific inhibition. The clinical experience with ACE-031 suggested that inhibiting BMP9 (a known angiogenesis factor) through ActRIIB contributed to vascular adverse effects. For understanding which ligands drive which effects, using both and comparing results can be informative.

ACE-031 was studied by Acceleron Pharma in Phase I and Phase II trials for Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease where myostatin inhibition was hypothesized to slow muscle loss. Phase I data showed increased lean mass and reduced fat mass, supporting the mechanism. Phase II was discontinued after observation of bleeding-related adverse events (epistaxis, gingival bleeding, telangiectasias) thought to be related to off-target inhibition of vascular BMP signaling through ActRIIB. This clinical experience has shaped subsequent development of more selective myostatin inhibitors.

Clinical discontinuation doesn't reduce research value -- it often increases it. ACE-031's clinical data established what broad ActRIIB ligand inhibition produces in humans: the expected muscle effects plus unexpected vascular effects from BMP9 inhibition. This creates a research tool with a known phenotypic profile in humans, useful for investigating which ActRIIB ligands mediate which effects. Comparing ACE-031 to myostatin-specific inhibitors in the same model allows researchers to attribute observed effects to specific ligands. The Fc fusion design also gives ACE-031 a long half-life suitable for chronic study designs.